SCHEMBL4529554

SCHEMBL4529554

CCn1cnc2c(=O)n(-c3ccc(Cl)cc3)c(CC(C)C(F)(F)F)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 1/20 0.41
DRD5 P21918 1/20 0.41
CNR1 P21554 4/20 0.39
HIF1A Q16665 1/20 0.37
TSHR P16473 3/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
XBP1 P17861 1/20 0.36
HTT P42858 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NPC1 O15118 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
SRC P12931 1/20 0.35
POLB P06746 1/20 0.34
AOC3 Q16853 1/20 0.34
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4522018 0.92 CNR1 (0.46) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4520614 0.91 CNR1 (0.40) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4978987 0.91 SMN1; SMN2 (0.37) TSHRALDH1A1LMNANPC1PDE4A
SCHEMBL4521631 0.90 TSHR (0.37) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4978421 0.89 SRC (0.33) DRD1DRD5CNR1TSHRALDH1A1
SCHEMBL4427544 0.88 DRD1 (0.44) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4978894 0.88 DRD1 (0.44) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4427546 0.88 DRD1 (0.44) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4519944 0.88 CNR1 (0.37) DRD1DRD5CNR1HIF1ATSHR
SCHEMBL4981916 0.88 DRD1 (0.40) DRD1DRD5CNR1HIF1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US claimed
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) BROWN REBECCA ELIZABETH 2009-12-03 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 DRD1 1261/4885DRD5 1056/4885CNR1 26/4885
US-20090298856-A1 2,3 Substituted fused bicyclic pyrimidin-4(3H)-ones modulating the function of the vanilliod-1receptor (VR1) TRPV1, TRPV2, TRPV4 DRD1 333/4885DRD5 695/4885CNR1 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.